Replies to post #224343 on Biotech Values

[Whalatane]

PRTO ..thx for the reply Poorgrad .

After my earlier post to you , I went back and re read your previous posts on PRTO.
I compared those with the bullish expectations the Ceo seemed to have about the final trial .....and decided to " curb my enthusiasm "....ie limit myself to a small speculative position.

Growing up in New Zealand , I spent time milking cows.
Being near the cows rear end in the milking process , invariably put you in line for an occasional slap across the face...... with the cows tail covered in fresh cow poop.
An unpleasant but not fatal experience.
Todays PRTO read out was for me ......the small biotech investors version of that experience.

I have other medium / small exposures ( in descending order ) in FGEN, RETA, CCXI, CARA, XBIT ,AXSM and SLNO.
If any of those look like a " cows tail covered in fresh cow poop " heading my way , to you ...please advise.

I have a large position in AMRN ...am a CAD patient and am on the drug . If that crashes just bury me in the nearest cow pasture.

Kiwi ....

[DewDiligence]

PRTO reverse-merges into ArTara Therapeutics:

https://www.globenewswire.com/news-release/2019/09/23/1919503/0/en/Proteon-Therapeutics-and-ArTara-Therapeutics-Agree-to-Combine.html

Proteon Therapeutics, Inc. (Nasdaq: PRTO…and ArTara Therapeutics, Inc., a private clinical stage biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet therapeutic needs, announced today that they have entered into a definitive agreement in which a wholly-owned subsidiary of Proteon will merge with ArTara in an all-stock transaction. The merged company will focus on advancing ArTara’s pipeline of transformative late-stage, de-risked rare and specialty diseases assets.

Upon stockholder approval, the combined company is expected to operate under the name ArTara Therapeutics, Inc. and trade on the Nasdaq Capital Market under the ticker symbol TARA.

…Under the terms of the merger agreement, on a pro-forma basis after closing of the merger and the closing of the financing, the current Proteon stockholders will own approximately 10% of the combined company, while ArTara security holders and new investors will own approximately 90% (on a fully diluted basis).